

IN THE CLAIMS:

SUB B2
AF

1. (Amended) A method of treating inflammatory bowel disease in a subject, said method comprising:

administering a medicament comprising an amount of a cytokine-producing non-invasive Gram-positive bacterial strain to said subject, wherein the administration of said medicament results in one or more of reduction of inflammation by at least 50% and prevention of onset of said inflammation.

SUB C2

2. (Amended) The method according to claim 1 wherein the cytokine is IL-10.

3. (Amended) The method according to claim 1 wherein the non-invasive Gram-positive bacterial strain is a *Lactococcus* species.

4. The method according to claim 3 wherein the *Lactococcus* species is *Lactococcus lactis*.

5. (Withdrawn from consideration).

AC SUB B3

6. (Amended) The method according to claim 1 wherein the bowel disease is Crohn's.

7. The method according to claim 1 wherein the medicament is administered in combination with at least one additional therapeutic agent.

8. (Amended) The method according to claim 7 wherein the at least one therapeutic agent includes at least one immunosuppressive drug.

SUB C2

9. (Amended) The method according to claim 7 wherein the co-administration of at least one additional therapeutic agent is sequential or simultaneous.

10. (Amended) The method according to claim 1 wherein the medicament is delivered through *in situ* synthesis by recombinant *Lactococcus lactis*.

11. (Amended) The method according to claim 2 wherein the non-invasive Gram-positive bacterial strain is a *Lactococcus* species.

12. The method according to claim 11 wherein the *Lactococcus* species is *Lactococcus lactis*.

13. (Withdrawn from consideration).

14. (Amended) The method according to claim 2 wherein the bowel disease is Crohn's disease.

15. The method according to claim 2 wherein the medicament is administered in combination with at least one additional therapeutic agent.

16. (Amended) The method according to claim 15 wherein the at least one therapeutic agent includes at least one immunosuppressive drug.

17. (Amended) The method according to claim 15 wherein the co-administration of at least one additional therapeutic agent is sequential or simultaneous.

ASB
5/12

18. (Amended) The method according to claim 2 wherein the medicament is delivered through *in situ* synthesis by recombinant *Lactococcus lactis*.

19. (Cancelled)

20. (Cancelled)